For: | Kim SE, Park MI, Park SJ, Moon W, Kim JH, Jung K, Kim HK, Lee YD. Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes. World J Gastroenterol 2017; 23(6): 1059-1066 [PMID: 28246480 DOI: 10.3748/wjg.v23.i6.1059] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v23/i6/1059.htm |
Number | Citing Articles |
1 |
Marina Valenzano, Alessandro Bisio, Giorgio Grassi. Helicobacter pylori and diabetes mellitus: a controversial relationship. Minerva Endocrinologica 2019; 44(3) doi: 10.23736/S0391-1977.19.03021-9
|
2 |
Natsuda Aumpan, Varocha Mahachai, Ratha‐korn Vilaichone. Management of Helicobacter pylori infection. JGH Open 2023; 7(1): 3 doi: 10.1002/jgh3.12843
|
3 |
Sung Eun Kim. Effect of Diabetes Mellitus on Helicobacter pylori Eradication Therapy. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2017; 17(2): 59 doi: 10.7704/kjhugr.2017.17.2.59
|
4 |
Anthony O'Connor, Dominique Lamarque, Javier P. Gisbert, Colm O'Morain. Treatment of Helicobacter pylori infection 2017. Helicobacter 2017; 22(S1) doi: 10.1111/hel.12410
|
5 |
Snehal Sambhaji Misal, Vedant Balasaheb Bhor, Ramaa Subramanian Chelakara. Structural Insights into Potent Anti-ulcer Agents for the Eradication of Helicobacter pylori. Anti-Infective Agents 2024; 22(5) doi: 10.2174/0122113525296549240402074618
|
6 |
Sung Eun Kim. Approach to Patients with Consecutive Helicobacter pylori Eradication Failure. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2023; 23(1): 15 doi: 10.7704/kjhugr.2023.0017
|
7 |
Hyun Lim, Chang Seok Bang, Woon Geon Shin, Jae Ho Choi, Jae Seung Soh, Ho Suk Kang, Young Joo Yang, Ji Taek Hong, Suk Pyo Shin, Ki Tae Suk, Jae Jun Lee, Gwang Ho Baik, Dong Joon Kim. Modified quadruple therapy versus bismuth-containing quadruple therapy in first-line treatment of Helicobacter pylori infection in Korea; rationale and design of an open-label, multicenter, randomized controlled trial. Medicine 2018; 97(46): e13245 doi: 10.1097/MD.0000000000013245
|
8 |
Sung Eun Kim, Ji Hun Roh, Moo In Park, Seun Ja Park, Won Moon, Jae Hyun Kim, Kyoungwon Jung, Jae Joon Heo. Effect of 7-day Bismuth Quadruple Therapy versus 14-day Moxifloxacin Triple Therapy for Second-line Helicobacter pylori Eradication Therapy. The Korean Journal of Gastroenterology 2019; 73(1): 26 doi: 10.4166/kjg.2019.73.1.26
|
9 |
Kiwon Shin, Min-Jae Cho, Jung-Hwan Oh, Chul-Hyun Lim. Second-Line Bismuth-Containing Quadruple Therapy for Helicobacterpylori Infection: A 12-Year Study of Annual Eradication Rates. Journal of Clinical Medicine 2021; 10(15): 3273 doi: 10.3390/jcm10153273
|
10 |
|
11 |
Sung Eun Kim. Can Proton Pump Inhibitors Affect Helicobacter pylori Eradication Therapy?. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2020; 20(3): 173 doi: 10.7704/kjhugr.2019.0050
|
12 |
Mohammed Mohammed, Dunya Arif, Mohsin Mohammed. THE EVALUATION OF TRIPLE, QUADRUPLE, AND LEVOFLOXACIN-BASED THERAPY IN THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION AMONG DYSPEPTIC PATIENTS. JOURNAL OF SULAIMANI MEDICAL COLLEGE 2019; 9(1): 45 doi: 10.17656/jsmc.10189
|
13 |
Gil Ho Lee, Kee Myung Lee, Sung Jae Shin, Joon Koo Kang, Choong-Kyun Noh, Jin Hong Kim, Sun Gyo Lim. Impact of previous metronidazole exposure on metronidazole-based second-line quadruple therapy for Helicobacter pylori infection . The Korean Journal of Internal Medicine 2020; 35(5): 1094 doi: 10.3904/kjim.2020.174
|
14 |
Jung Won Lee, Nayoung Kim, Ryoung Hee Nam, Sun Min Lee, Choi Soo In, Jung Mogg Kim, Dong Ho Lee. Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication. Journal of Gastroenterology and Hepatology 2019; 34(4): 666 doi: 10.1111/jgh.14625
|
15 |
Xin Song, Changzhou Cai, Qi Jin, Xueyang Chen, Chaohui Yu. The efficacy of Helicobacter pylori eradication in diabetics and its effect on glycemic control: A systematic review and meta‐analysis. Helicobacter 2021; 26(2) doi: 10.1111/hel.12781
|